Rapalogix Health

Rapalogix is advancing a portfolio of TORC1-selective therapies and pro-longevity skincare products, addressing skin aging and disease at the root to extend skin healthspan.

Rapalogix Health publishes a double-blind clinical study in the *Journal of Cosmetic Dermatology* demonstrating that its **Re-Q Longevity Face Serum** improves skin firmness, elasticity, and biomechanics as early as **Week 2**. The peer-reviewed results show significant improvements compared to a placebo, with findings supported by **TORC1 pathway suppression** in human skin models.

Oct 2026Yahoo FinanceNews article

Rapalogix Health opens a dedicated research laboratory at Princeton Innovation Center BioLabs to develop next-generation rapalogs, the proprietary compounds behind its longevity-focused skin health product **Re-Q H**. The facility strengthens the company’s internal research capacity and houses its translational research program. Rapalogix specializes in biotechnology solutions targeting skin health through longevity-based approaches.

Sep 2026Yahoo FinanceNews article

Rapalogix secures $20 million in Series A funding to expand its **Re-Q** product line and advance a pipeline based on **mTOR biology**. The company targets commercial applications in **longevity-focused skin health**, aiming to translate scientific research into market-ready solutions.

Jun 2026Longevity.TechnologyNews article

Rapalogix Health secures Series A funding co-led by Woodline Partners and GordonMD Global Investments. The round supports the health-focused company’s growth and development. Rapalogix operates in the life sciences sector, though specific use cases or technologies are not detailed in the announcement.

Jun 2026dealroom.coNews article